SARS-CoV-2 Delta variant

It has mutations in the gene encoding the SARS-CoV-2 spike protein^[6] causing the substitutions T478K, P681R and L452R,^[7][8] which are known to affect transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus.^[9] In August 2021, Public Health England (PHE) reported secondary attack rate in household contacts of non-travel or unknown cases for Delta to be 10.8% vis-à-vis 10.2% for the Alpha variant;^[10] the case fatality rate for those 386,835 people with Delta is 0.3%, where 46% of the cases and 6% of the deaths are unvaccinated and below 50 years old.^[11] Immunity from previous recovery^[12][13] or COVID-19 vaccines are effective in preventing severe disease or hospitalisation from infection with the variant.^[14]


On 7 May 2021, PHE changed their classification of lineage B.1.617.2 from a variant under investigation (VUI) to a variant of concern (VOC) based on an assessment of transmissibility being at least equivalent to B.1.1.7 (Alpha variant);^[15] the UK's SAGE using May data estimated a "realistic" possibility of being 50% more transmissible.^[16] On 11 May 2021, the WHO also classified this lineage VOC, and said that it showed evidence of higher transmissibility and reduced neutralisation. On 15 June 2021, the Centers for Disease Control and Prevention (CDC) declared Delta a variant of concern.^[17]


The variant is thought to be partly responsible for India's deadly second wave of the pandemic beginning in February 2021.^[18][19][20] It later contributed to a third wave in Fiji, the United Kingdom^[21][22][23] and South Africa,^[24] and the WHO warned in July 2021 that it could have a similar effect elsewhere in Europe and Africa.^[25][24] By late July, it had also driven an increase in daily infections in parts of Asia,^[26] the United States,^[27] Australia, and New Zealand.^[28]